Daiichi Sankyo

Encouraging trial results for Daiichi anti-stroke therapy
Encouraging trial results for Daiichi anti-stroke therapy
The Pharma Letter
Daiichi Sankyo
Lixiana
edoxaban
clinical trials
atrial fibrilation
stroke
Flag link:
Daiichi Sankyo in pursuit of Novartis’ Rydapt with next-generation FLT3 drug
Daiichi Sankyo in pursuit of Novartis’ Rydapt with next-generation FLT3 drug
Fierce Biotech
Novartis
Rydapt
acute myeloid leukemia
Daiichi Sankyo
quizartinib
Flag link:
Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development
Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development
Endpoints
Daiichi Sankyo
Duchenne Muscular Dystrophy
DS-5141
Flag link:
Could This be the End of Flu Shots?
Could This be the End of Flu Shots?
CP Wire
Vaxart
influenza vaccines
Daiichi Sankyo
vaccines
oral vaccines
Flag link:
Could This be the End of Flu Shots? - Updated
Vaxart
influenza vaccines
Daiichi Sankyo
Flag link:
Top 5 boards for week ending March 10, 2018
Top 5 boards for week ending March 10, 2018
CP Wire
Daiichi Sankyo
Shire
Amgen
Sanofi
AstraZeneca
Flag link:
3 Things In Biotech, March 8: A Tale Of 3 New Trials
3 Things In Biotech, March 8: A Tale Of 3 New Trials
Seeking Alpha
biotech
clinical trials
Seattle Genetics
SGN-CD48A
Daiichi Sankyo
DS-8201
HER-positive colorectal cancer
Allena Pharmaceuticals
hyperoxaluria
Flag link:
Top 5 viewed boards for week ending March 3, 2018
Top 5 viewed boards for week ending March 3, 2018
CP Wire
cafepharma
Daiichi Sankyo
Shire
Allergan
Amgen
Sanofi
sales meeting
layoffs
Esmya
Pfizer
Celgene
M&A
Flag link:
Daiichi Sankyo douses a report about an AstraZeneca buyout offer
Daiichi Sankyo douses a report about an AstraZeneca buyout offer
Endpoints
AstraZeneca
Daiichi Sankyo
M&A
Flag link:
Daiichi Sankyo punts $650M collaboration pact as Charleston Labs preps a comeback attempt on spurned pain drug
Daiichi Sankyo punts $650M collaboration pact as Charleston Labs preps a comeback attempt on spurned pain drug
Endpoints
Daiichi Sankyo
Charleston Laboratories
CL-108
painkillers
Flag link:
Daiichi Sankyo hands off cancer drug to Boston Pharma
Daiichi Sankyo hands off cancer drug to Boston Pharma
BioPharma Dive
Boston Pharmaceuticals
Daiichi Sankyo
DS-5010
cancer
Flag link:
Daiichi Sankyo settles U.S. lawsuits over blood pressure drug Benicar
Daiichi Sankyo settles U.S. lawsuits over blood pressure drug Benicar
Reuters
Daiichi Sankyo
Benicar
Flag link:
EMA Backs Eight New Medicines, Turns Down Drugs From Nektar & Vanda
EMA Backs Eight New Medicines, Turns Down Drugs From Nektar & Vanda
RAPS.org
EMA
Europe
Pfizer
Bavencio
Novartis
Rydapt
Lexicon Pharmaceuticals
Xermelo
Vanda
Fanaptum
Nektar
Onzeald
Daiichi Sankyo
Flag link:
Nektar’s pitch on early cancer drug OK runs into a regulatory brick wall
Nektar’s pitch on early cancer drug OK runs into a regulatory brick wall
Endpoints
Nektar
regulatory
Onzeald
Europe
Daiichi Sankyo
Flag link:
In latest setback, another Coherus partner bails out on Amgen biosimilar deal
In latest setback, another Coherus partner bails out on Amgen biosimilar deal
Endpoints
Coherus
Amgen
biosimilars
Daiichi Sankyo
CHS-0214
rheumatoid arthritis
Enbrel
Flag link:
Daiichi Sankyo sweeps out Pieris drug, 5 others in a Q1 pipeline cleanup
Daiichi Sankyo sweeps out Pieris drug, 5 others in a Q1 pipeline cleanup
Endpoints
Daiichi Sankyo
Pieris
DS-9001
tivantinib
Arqule
Flag link:
Daiichi Sankyo to invest $135M in ADC manufacturing expansion
Daiichi Sankyo to invest $135M in ADC manufacturing expansion
BioPharma Dive
Daiichi Sankyo
drug manufacturing
antibody-drug conjugate
Flag link:
Daiichi, ArQule cancer drug fails in late-stage study
Daiichi, ArQule cancer drug fails in late-stage study
BioPharma Dive
Daiichi Sankyo
Arqule
clinical trials
tivantinib
liver cancer
Flag link:
Daiichi shutters Japanese plant amid restructuring efforts
Daiichi shutters Japanese plant amid restructuring efforts
BioPharma Dive
Daiichi Sankyo
Japan
restructuring
Flag link:
Daiichi Sankyo shutters another R&D center in an ongoing global overhaul
Daiichi Sankyo shutters another R&D center in an ongoing global overhaul
Endpoints
Daiichi Sankyo
R&D
restructuring
Flag link:

Pages